Fig. 4From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalMethylation pattern at time of disease progression after initial response is not similar to methylation pattern from those patients that have never respond (non-responders). Heatmap showing the hierarchical clusterization of samples from patients in progression (n =12) in comparison with responder (n =21) and non-responder (n =16) patients at diagnosis based on DNA methylation of the sites identified in Fig. 2Back to article page